Next Article in Journal
Growing Teratoma Syndrome in the Setting of Sarcoidosis: A Case Report and Literature Review
Previous Article in Journal
Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective
 
 
Article

Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients

1
Department of Pediatric Oncology, Faculty of Medicine, University Hospital Brno and Masaryk University, Cernopolni 9, 613 00 Brno, Czech Republic
2
Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic
3
Department of Laboratory Medicine, University Hospital Brno, Jihlavska 20, 625 00 Brno, Czech Republic
4
Department of Biochemistry, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
5
Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
6
Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic
7
Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Žlutý kopec 7, 625 00 Brno, Czech Republic
8
Department of Internal Cardiology Medicine, Faculty of Medicine, University Hospital Brno and Masaryk University, Jihlavska 20, 625 00 Brno, Czech Republic
9
Department of Laboratory Methods, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
10
The International Clinical Research Centre of St. Anne’s University Hospital in Brno, Pekarska 53, 656 91 Brno, Czech Republic
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(6), 4138-4147; https://doi.org/10.3390/curroncol29060330
Received: 9 May 2022 / Revised: 31 May 2022 / Accepted: 5 June 2022 / Published: 7 June 2022
Sunitinib is a broad-spectrum multitargeted tyrosine kinase inhibitor mainly used as second-line therapy for non-resectable gastrointestinal stromal or first-line treatment option of metastatic renal cell carcinoma (mRCC), and as an “off-label” option in pediatric oncology. It has been previously reported that sunitinib elevates the mean corpuscular volume of erythrocytes (MCV) in treated subjects. The aim of this study was to assess time-dependent changes of this effect and evaluate its possible clinical relevance. In this study, 179 adult and 21 pediatric patients with solid tumors treated with sunitinib were retrospectively analyzed. The laboratory and treatment-related data were collected for each treatment period. The regression model with a broken-line relationship was used to fit time dependence of the MCV. In the adult group, the MCV was increasing during the first 21.6 weeks (median) of treatment in a median level of 99.8 fL, where it stabilized. MCV increase was faster in the patients who suffered from treatment-related adverse events (21.3 vs. 24.6 weeks, p = 0.010). In the pediatric cohort, the MCV dynamics were similar to adults. In conclusion, MCV changes during sunitinib treatment in pediatric and adult patients may be of clinical utility in monitoring sunitinib treatment course. View Full-Text
Keywords: sunitinib; mean corpuscular volume; MCV; toxicity sunitinib; mean corpuscular volume; MCV; toxicity
Show Figures

Figure 1

MDPI and ACS Style

Rihacek, M.; Selingerova, I.; Kocak, I.; Kocakova, I.; Rihackova, E.; Valik, D.; Sterba, J. Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients. Curr. Oncol. 2022, 29, 4138-4147. https://doi.org/10.3390/curroncol29060330

AMA Style

Rihacek M, Selingerova I, Kocak I, Kocakova I, Rihackova E, Valik D, Sterba J. Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients. Current Oncology. 2022; 29(6):4138-4147. https://doi.org/10.3390/curroncol29060330

Chicago/Turabian Style

Rihacek, Michal, Iveta Selingerova, Ivo Kocak, Ilona Kocakova, Eva Rihackova, Dalibor Valik, and Jaroslav Sterba. 2022. "Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients" Current Oncology 29, no. 6: 4138-4147. https://doi.org/10.3390/curroncol29060330

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop